Kadmos Capital is a UK-based venture capital fund focused on early-stage deep-tech companies with positive impact across artificial intelligence, sustainability and longevity.
The oversubscribed round was led by Oyster Bay Venture Capital to advance research and development on plant-based materials.
"Once optimised and patented, we will raise our next round to co-locate this continuous process alongside a brewery, enabling immense production outputs. We initially applied our technology to beer breweries and whisky distilleries because of their robust supply chains. As part of this raise, we will also prioritise commercial partnerships to introduce products to the fashion and other industries, starting on a small scale."
The latest investment brings total equity financing to £7.2m and will support clinical progression of internal assets.
"A third of all FDA-approved drugs target GPCRs, yet, despite decades of research and billions of funding, only a few GPCR-targeting antibodies exist. Thanks to the support of our investors, we are one step closer to making GPCRs and other challenging targets druggable, bringing needed therapies to patients across the globe."
The financing round was led by LAUNCHub Ventures and Kadmos Capital to fund the company's shift towards the diagnostics market.
"We are thrilled to have the support of LAUNCHub Ventures and Kadmos Capital, who share our vision for a healthier future. This funding round marks a significant milestone for GlycanAge, and we are excited to continue our journey towards transforming healthcare and empowering individuals to take control of their well-being."
The financing was supported by new investors including InnoSpark alongside returning backers such as the Development Bank of Wales.
"This is the most comprehensive validation of our platform thus far. While identifying antibodies to GPCRs has traditionally been a complex and time-intensive process requiring expensive specialist technology and training, we have demonstrated that Antiverse’s drug discovery platform can achieve this in a fraction of the time and cost. GPCRs are commercially interesting targets associated with various indications, and these antibodies offer a path to first in vivo results and can potentially be our first assets. I would like to thank our investors, this funding will enable us to continue to develop these assets in-house with our academic collaborators."
.png)
